Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant I...
Georgina V. Long, I. Pires da Silva, Kristen A. Perry et al.· Nature Medicine· 0 citations
PURPOSE
Mucosal melanoma (MM) is a rare subtype of melanoma with inferior response rates and outcomes to immunotherapy. Vascular endothelial growth factor (VEGF) signaling may contribute to immune resistance and represents a potential therapeutic target. We evaluated nivolumab plus axitinib in untreated, advanced MM in...
S. Lochrin, H. Kalvin, Monica F. Chen et al.· Clinical Cancer Research· 0 citations
Although a heritable component is implicated in ~10% of melanomas, the prevalence and functional relevance of germline pathogenic variants (gPVs) in unselected patients remains unknown. We evaluated 701 patients with melanoma who underwent tumor-normal MSK-IMPACT sequencing (2015–2023) and germline analysis of ≥76 ca...
S. Lochrin, H. Walch, Y. Kemel et al.· npj Genomic Medicine· 0 citations
CUP melanomas in self-ID POC had lower median TMB and were more likely to be pan-wildtype, reflecting differences in pathogenesis, and larger scale studies are needed to validate these findings.
J. Ross, V. Weir, Leore Lavin et al.· Journal of American Academy...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.